Posted by Michael Wonder on 01 Oct 2018
HighTide Therapeutics receives fast track designation from the U.S. FDA for HTD1801 treating primary sclerosing cholangitis
27 September 2018 - HighTide Therapeutics announced that the U.S. FDA has granted fast track designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholangitis.
HighTide completed a first in human study of HTD1801 in healthy volunteers. A multi-center Phase 2 trial in adult patients with primary sclerosing cholangitis is currently enrolling in the United States.
